Dogwood Therapeutics Inc. Common Stock (DWTX)
Stock · NASDAQ · Health Care
$1.25as of 10/16/2026
Price chart
Active signals
DWTX Signal Track Record
How signals performed across all stocks →What DWTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -6.7% | 44% | October 6, 2026 |
| Bollinger Band Breakout | 25 | -7.9% | 36% | August 19, 2026 |
| Bollinger Band Breakdown | 18 | +1.5% | 56% | June 5, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -0.5% | 44% | November 11, 2025 |
| Any 20-session window (baseline) | -3.2% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DWTX
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and can…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- dwtx.com/
Fundamentals
- 1-day range
- $1.18$1.29
- Market cap
- $58.85M
- P/E (trailing)
- —
- P/E (forward)
- -0.20
- EPS (trailing)
- $-10.60
- Dividend yield
- —
- Beta
- 2.14
- Avg. volume
- 65.7K
Forecasts
3 analyst ratings
Dogwood Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DWTXDogwood Therapeutics Inc. Common Stock$1.22▼ 2.40%Market cap $58.85MP/E —$1.24$7.04
- HYFTMindWalk Holdings Corp. Common Stock$1.31▼ 6.43%Market cap $59.79MP/E —$0.99$2.99
- IMMPImmutep Limited American Depositary Shares$3.2▼ 0.31%Market cap $55.21MP/E —$0.022$0.47
- INCRIntercure Ltd. Ordinary Shares$4.57▼ 1.72%Market cap $54.80MP/E —$253.3$2,740
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.21▼ 6.20%Market cap $62.93MP/E —$1.02$1.91
- BOLDBoundless Bio Inc. Common Stock$2.34▼ 0.43%Market cap $63.80MP/E —$0.9612$3.16
- ANVSAnnovis Bio Inc. Common Stock$0.99▼ 5.71%Market cap $64.44MP/E —$1.01$5.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DWTX Dogwood Therapeutics Inc. Common Stock | $58.85M | — | $1.22 | ▼ 2.40% | $1.24$7.04 |
| HYFT MindWalk Holdings Corp. Common Stock | $59.79M | — | $1.31 | ▼ 6.43% | $0.99$2.99 |
| IMMP Immutep Limited American Depositary Shares | $55.21M | — | $3.2 | ▼ 0.31% | $0.022$0.47 |
| INCR Intercure Ltd. Ordinary Shares | $54.80M | — | $4.57 | ▼ 1.72% | $253.3$2,740 |
| PMVP PMV Pharmaceuticals Inc. Common Stock | $62.93M | — | $1.21 | ▼ 6.20% | $1.02$1.91 |
| BOLD Boundless Bio Inc. Common Stock | $63.80M | — | $2.34 | ▼ 0.43% | $0.9612$3.16 |
| ANVS Annovis Bio Inc. Common Stock | $64.44M | — | $0.99 | ▼ 5.71% | $1.01$5.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Dogwood to Participate in the 2026 Maxim Growth SummitYahoo · 10/6/2026
- Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialYahoo · 9/14/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/11/2026
Insider Activity
Insider Actions →- Whitley Richard James · June 16, 2026 · Grant16.8K
- Thomas John C · June 16, 2026 · Grant16.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.56M
- Total value held
- $7.51M
- Institutional holders
- 12
- Unknown3.28M
- Unknown132.2K
- Unknown79.4K
- Unknown23.8K
- Unknown14.6K
- Unknown11.8K
- Unknown8.1K
- Unknown7.1K
- Unknown120
- Unknown30
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Dogwood to Join 2026 Maxim Growth Summit
Dogwood Therapeutics announced it will participate in the 2026 Maxim Growth Summit. The event is aimed at showcasing companies to investors and partners. Participation may raise the company’s profile and provide networking opportunities. The announcement comes as the stock trades near its 14‑touch support level.
Dogwood to Join 2026 Maxim Growth Summit. Dogwood Therapeutics announced it will participate in the 2026 Maxim Growth Summit. The event is aimed at showcasing companies to investors and partners. Participation may raise the company’s profile and provide networking opportunities. The announcement comes as the stock trades near its 14‑touch support level.